Welcome to our dedicated page for ABPRO HLDGS news (Ticker: ABP), a resource for investors and traders seeking the latest updates and insights on ABPRO HLDGS stock.
Abpro Corporation (ABP) is a clinical-stage biotech company developing novel antibody therapies for cancer and eye diseases. This page aggregates official news and regulatory filings related to their therapeutic pipeline, strategic partnerships, and corporate developments.
Investors and researchers will find timely updates on clinical trial progress for lead candidates including ABP-102 (HER2+ cancers) and ABP-201 (macular degeneration). The repository includes SEC filings, partnership announcements with organizations like Celltrion, and manufacturing updates.
Key content types include: clinical trial milestones, regulatory submissions, intellectual property developments, and financial reporting. All materials are sourced from official company communications to ensure reliability.
Bookmark this page for consolidated access to Abpro's latest scientific advancements and corporate news. Check back regularly for updates on their Nasdaq listing progress and pipeline expansion.
Abpro (Nasdaq: ABP) received a Nasdaq Hearings Panel extension to regain full compliance with listing requirements on Dec 9, 2025. The company completed a reverse stock split effective Nov 3 and says it has a compliance roadmap that includes a market transfer application and a planned capital strategy to increase stockholders' equity. Abpro reports an estimated ~60% reduction in operating expenses year-over-year and access to up to $44 million in equity financing to fund operations and milestones through 2026. The lead candidate ABP-102 is on track for first-in-human trials in 2026.
Abpro (Nasdaq: ABP) and Celltrion will present preclinical data for CT-P72/ABP-102, a tetravalent HER2×CD3 bispecific, at SITC 2025 on Nov 7, 2025. The poster was selected among the Top 150 of >1,300 abstracts. Key preclinical findings show potent, selective anti-tumor activity in HER2-high models, activity in Enhertu-resistant tumors, robust T-cell activation and cytokine release in human PBMC assays, and efficacy in multiple xenograft models.
GLP toxicity testing in cynomolgus monkeys (4-week dosing + 4-week recovery) showed tolerability up to 80 mg/kg, supporting advancement toward first-in-human studies and an IND package.
Abpro (Nasdaq: ABP) announced its previously approved 1-for-30 reverse stock split became effective Oct 31, 2025 and trading will be split-adjusted at the open on Nov 3, 2025. At the effective time every 30 shares combined into one; the company will not issue fractional shares and fractions will be rounded up.
Outstanding shares will fall from ~81.2 million to 2.7 million. Options and warrants will be proportionally adjusted. The company cited the Reverse Stock Split as a step to maintain Nasdaq compliance while pursuing a capital-efficient growth phase after an estimated ~60% reduction in operating costs. Celltrion will fund all development expenses for lead program ABP-102, with a first-in-human trial anticipated in 2026.
Abpro Holdings (Nasdaq:ABP) and Celltrion presented preclinical data for their co-developed ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-cell engager, at AACR 2025. The therapy targets HER2-overexpressing tumors, which represent up to 30% of breast, gastric, pancreatic, colorectal, and other cancers.
Key findings show:
- Up to 2x increase in tumor suppression compared to runimotamab biosimilar
- Enhanced tumor-selective cytotoxicity in HER2-overexpressing cancer models
- Reduced cytokine release in HER2-low cells
- Superior tolerability in cynomolgus monkeys at 180x maximum tolerated dose of parental antibody
Clinical trials are scheduled to begin in H1 2026.
Abpro Holdings (Nasdaq: ABP) has announced an upcoming oral presentation of preclinical data for their drug candidate ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-Cell Engager, at the AACR Annual Meeting 2025. The presentation will take place during the New Drugs on the Horizon session at McCormick Place Convention Center in Chicago, between April 25-30.
The company, which focuses on developing next-generation antibody therapies for severe and life-threatening diseases, has established a strategic partnership with Celltrion for the worldwide development and commercialization of ABP-102/CT-P72.
Abpro Holdings (Nasdaq:ABP) announced the departure of CEO Ian Chan, with Board Chairman Miles Suk assuming the CEO position. The company emphasized that this leadership transition will not impact their strategic direction or stability.
The company reaffirmed its commitment to ABP 102/CT-P72, their joint development project with Celltrion. Chief Medical Officer Robert J. Markelewicz highlighted that initial data indicates ABP-102/CT-P72 could be potentially best-in-class for HER2-positive cancers, which affect up to 30% of breast, gastric, pancreatic, and other cancer cases. Additional data will be presented at an upcoming scientific meeting in spring.
Abpro Holdings (Nasdaq:ABP) celebrated its business combination closure with Atlantic Coastal Acquisition Corp II through a Nasdaq bell ringing ceremony. The company raised $10 million in gross proceeds, including a $7 million PIPE offering and $2.76 million convertible note financing.
Additional financing arrangements include a $50 million standby equity purchase agreement with Yorkville, potential for $2 million in additional debt financing, and a forward purchase agreement for up to 500,000 shares of common stock. These funds will support Abpro's development of next-generation antibody therapies for cancer, ophthalmology, and infectious diseases.
The company has partnered with Celltrion to advance ABP 102, a T-cell engager for treating HER2+ breast, gastric, and pancreatic cancers. Abpro's pipeline focuses on multiple cancer types, wet age-related macular degeneration (AMD), and diabetic macular edema (DME), utilizing their proprietary DiversImmune® platform.
FAQ
What is the current stock price of ABPRO HLDGS (ABP)?
What is the market cap of ABPRO HLDGS (ABP)?
